Status

2019 report now available

Corporate reputation of Pharma 2019

From the patient perspective 2019-2020

From 1st November 2019 to 26th February 2020, PatientView asked patient groups around the world to comment on the reputation of the pharmaceutical industry and individual companies within it.

  • The survey was conducted in 20 languages:

Danish | Dutch | English | Finnish | French | German | Greek | Hungarian | Italian | Japanese | Korean | Norwegian | Portuguese | Polish | Russian | Spanish | Swedish | Simplified Chinese | Traditional Chinese | Turkish.

  • Companies included in the 2020 publications of the corporate reputation survey:

AbbVie I Acorda Therapeutics I Allergan I Almirall I Amgen I Astellas Pharma I AstraZeneca I Bayer I Bial I Biogen I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Chiesi Farmaceutici I CSL Behring I Daiichi Sankyo I Eisai I Eli Lilly (Lilly) I Ferring I Gedeon Richter I Gilead/Kite Pharma I Grifols I Grünenthal I GSK I Ipsen I Janssen I LEO Pharma I Lundbeck I Menarini I Merck & Co (MSD outside of the US) I Merck KGaA/EMD Group I Novartis I Novo Nordisk I Octapharma I Otsuka I Pfizer I Pierre Fabre Laboratories I Roche (Genentech in the US, Chugai in Japan) I Sanofi I Servier I Takeda (including Shire) I Teva I UCB I Vertex Pharmaceuticals I Vifor I ViiV Healthcare

  • Industry and companies were assessed for their performance at 12 indicators from the perspective of patient groups:

    • Patient centricity
    • Quality of patient information
    • Safety provided to patients
    • Usefulness and benefits of products to patients
    • Transparency (clinical data, funding of external stakeholders, pricing policies)
    • Provision of services ‘beyond the pill’
    • Integrity
    • The quality of patient-group partnerships;
    • Patient engagement in R&D.

  • The first data analysis in April 2020 looked at pharma reputation from a global viewpoint.

Other analyses produced during the year include:

Therapy areas: Autoimmune | Bleeding disorders (published)| Cancer (published) | HIV/AIDS (published) | Mental health | Neurological | Rare diseases | and Respiratory (published) [8datasets/reports].
Geographic areas: global (pubnlished) Canada (published)| Germany | Italy (published) | Asia | Spain | the UK (published) | and the USA (published) [8 datasets /reports].